BL-1249

• UNSPSC Description:

  BL-1249 is a nonsteroidal anti-inflammatory agent (NSAID) and a potassium channel activator. BL-1249 potently activates K2P2.1 (TREK-1) and K2P10.1 (TREK-2) with EC50 values of 5.5 μM and 8.0 μM, respectively. BL-1249 extracellular application activates all TREK subfamily members but has no effect on other K2P subfamilies. BL-1249 exhibits more selective for the bladder (EC50 of 1.26 μM) than vascular tissue (EC50 of 21.0 μM)[1][2].

• Target Antigen:

  Potassium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/bl-1249.html

• Purity:

  99.81

• Solubility:

  DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  C1(NC2=C3CCCCC3=CC=C2)=CC=CC=C1C4=NN=NN4

• Molecular Weight:

  291.35

• References & Citations:

  [1]Tertyshnikova S, et al. BL-1249 [(5,6,7,8-tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine]: a putative potassium channel opener with bladder-relaxant properties. J Pharmacol Exp Ther. 2005 Apr;313(1):250-9.|[2]Pope L, et al. Protein and Chemical Determinants of BL-1249 Action and Selectivity for K2P Channels. ACS Chem Neurosci. 2018 Dec 19;9(12):3153-3165.|[3]Iwaki Y, et al. Towards a TREK-1/2 (TWIK-Related K+ Channel 1 and 2) dual activator tool compound: Multi-dimensional optimization of BL-1249. Bioorg Med Chem Lett. 2019 Jul 1;29(13):1601-1604.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  18200-13-0